Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?

We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Diagnostics (Basel)
Auteurs principaux: Santoni, Matteo, Massari, Francesco, Bracarda, Sergio, Procopio, Giuseppe, Milella, Michele, De Giorgi, Ugo, Basso, Umberto, Aurilio, Gaetano, Incorvaia, Lorena, Martignetti, Angelo, Rizzo, Mimma, Cartenì, Giacomo, Grande, Enrique, Matrana, Marc R., Crabb, Simon J., Vau, Nuno, Sorgentoni, Giulia, Cimadamore, Alessia, Montironi, Rodolfo, Battelli, Nicola
Format: Artigo
Langue:Inglês
Publié: MDPI 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7831923/
https://ncbi.nlm.nih.gov/pubmed/33477676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/diagnostics11010138
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires